HomeABCL • NASDAQ
add
AbCellera Biologics Inc
Previous close
$4.61
Day range
$4.45 - $4.70
Year range
$1.89 - $5.82
Market cap
1.34B USD
Avg Volume
4.80M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 17.08M | 133.29% |
Operating expense | 27.46M | -54.13% |
Net income | -34.73M | 5.97% |
Net profit margin | -203.27 | 59.69% |
Earnings per share | -0.12 | 7.69% |
EBITDA | -44.11M | 22.51% |
Effective tax rate | 4.45% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 553.08M | -17.49% |
Total assets | 1.40B | -0.74% |
Total liabilities | 394.98M | 31.00% |
Total equity | 1.01B | — |
Shares outstanding | 298.83M | — |
Price to book | 1.35 | — |
Return on assets | -9.03% | — |
Return on capital | -11.07% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -34.73M | 5.97% |
Cash from operations | -32.40M | -8.14% |
Cash from investing | -31.81M | -161.06% |
Cash from financing | -3.38M | -227.31% |
Net change in cash | -66.83M | -370.13% |
Free cash flow | -61.07M | -43.54% |
About
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
CEO
Founded
2012
Headquarters
Website
Employees
596
